Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Equity Average (2016 - 2025)

Amicus Therapeutics' Equity Average history spans 15 years, with the latest figure at $252.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 35.35% year-over-year to $252.3 million, compared with a TTM value of $252.3 million through Dec 2025, up 35.35%, and an annual FY2025 reading of $234.1 million, up 32.2% over the prior year.
  • Equity Average for Q4 2025 was $252.3 million at Amicus Therapeutics, up from $217.4 million in the prior quarter.
  • The five-year high for Equity Average was $342.0 million in Q4 2021, with the low at $107.1 million in Q2 2023.
  • Average Equity Average over 5 years is $193.4 million, with a median of $190.1 million recorded in 2024.
  • Year-over-year, Equity Average tumbled 62.63% in 2022 and then surged 51.15% in 2025.
  • Tracing FOLD's Equity Average over 5 years: stood at $342.0 million in 2021, then tumbled by 62.63% to $127.8 million in 2022, then grew by 14.79% to $146.7 million in 2023, then rose by 27.08% to $186.4 million in 2024, then soared by 35.35% to $252.3 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Equity Average are $252.3 million (Q4 2025), $217.4 million (Q3 2025), and $198.9 million (Q2 2025).